MD Anderson names new vice provost, clinical and interdisciplinary research
MD Anderson News Release 06/30/2015
The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, M.D., as vice provost for clinical and interdisciplinary research. Dr. Wilding’s appointment at MD Anderson will begin on September 1st.
Prior to joining MD Anderson, Dr. Wilding served on the institution’s external advisory board. He also served as chair of the Moon Shots...
Similarities between embryos and breast tumors identified
MD Anderson researchers find that metastatic tumors behave like embryonic stem cells
MD Anderson News Release 06/30/2015
Tiny particles in blood useful for early diagnosis of pancreatic cancer
MD Anderson study shows promise for Glypican-1 in identifying cancer-specific exosomes
MD Anderson News Release 06/24/2015
<...
Keys to prevention: MD Anderson leaders share latest news in fight to end cancer
Making Cancer History® seminar returns to Aspen July 16
MD Anderson News Release 06/24/2015
The University of Texas MD Anderson Cancer Center heads to Aspen this summer for its 17th annual Making Cancer History® seminar. The free event is slated for 1-3 p.m. on July 16 at Aspen Meadows Resort’s Paepcke Auditorium, 1000 N. Third St.
Seating is limited. Registration is requested at 866-434-7084, press 5, or events...
Current blood cancer drug prices not justified, MD Anderson study finds
MD Anderson News Release 06/22/2015
The costs associated with cancer drug prices have risen dramatically over the past fifteen...
Genomic discovery of skin cancer subtypes provides potential ‘signpost’ for drug targets
MD Anderson researchers lead The Cancer Genome Atlas analysis of cutaneous melanoma identifying four subtypes
MD Anderson News Release...
Breast-Conserving Therapy for Early-stage Cancers has Increased Substantially, Though Access Remains an Issue
Largest, most in-depth study to date shows BCT is being used more widely; health policy interventions are needed to address factors that prevent...
What’s in a name? “Death-associated protein” promotes cancer growth in most aggressive breast cancers
MD Anderson study identifies DAPK1 protein as a novel therapeutic target in tumors with TP53 mutations
MD Anderson News Release 06...
ADAMTS family of genes may be the next ‘thing’ in ovarian cancer treatment
MD Anderson study reveals key mutations other than well-known BRCA1/BRCA2 genes
MD Anderson News Release 06/11/2015
MD Anderson study finds gene mutations sensitize tumors to specific cancer drugs
Commonly mutated tumor suppressor represents a new target for treating certain cancers
MD Anderson News Release 06/11/2015